Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial

Published:2020-12 Issue:12 Volume:7 Page:e874-e883
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Roussel Murielle,Moreau Philippe,Hebraud Benjamin,Laribi Kamel,Jaccard Arnaud,Dib Mamoun,Slama Borhane,Dorvaux Véronique,Royer Bruno,Frenzel Laurent,Zweegman Sonja,Klein Saskia K,Broijl Annemiek,Jie Kon-Siong,Wang Jianping,Vanquickelberghe Veronique,de Boer Carla,Kampfenkel Tobias,Gries Katharine S,Fastenau John,Sonneveld Pieter

Publisher

Elsevier BV

Subject

Hematology

Reference25 articles.

1. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life;Baz;Support Care Cancer,2015

3. Frontline therapy of multiple myeloma;Moreau;Blood,2015

4. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma;Engelhardt;Haematologica,2014

5. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Moreau;Ann Oncol,2017

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma;Blood;2024-07-25

2. Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece;Clinical Lymphoma Myeloma and Leukemia;2024-07

3. General population normative values for the EORTC QLQ-C30 by age, sex, and health condition for the French general population;Journal of Patient-Reported Outcomes;2024-05-02

5. Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation;Cancers;2024-03-28